Corvas Selects Lead Antithrombotic
- Corvas has selected a lead antithrombotic, called NAPc2, from its stable of compounds derived from the hookworm. The molecular cloning and anticoagulant properties of the drug are discussed in the Proceedings of the National Academy of Sciences (March 5). NAPc2 should enter clinical testing for venous thromboses in 1997. Meantime, the company notes that NAPc2 inhibits the enzymatic complex of Factor VIIa and tissue factor by a unique mechanism of action, and appears to be almost 1,000 times more potent than low-molecular weight heparin (enoxaparin).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze